Estimated delivery in United States, on Tuesday 21 Jan 2025
Product Information
Name:
Indobufen
Controlled Product
Synonyms:
- 2-[4-(3-oxo-1H-isoindol-2-yl)phenyl]butanoic acid
- (2R)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]butanoic acid
- 1-Oxo-2-[p-[(α-ethyl)carboxymethyl]phenyl]isoindoline
- 2-(4-(1-Oxoisoindolin-2-yl)phenyl)butanoic acid
- 2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]butanoic acid
- 2-[p-(1-Oxo-2-isoindolinyl)phenyl]butyric acid
- 4-(1,3-Dihydro-1-oxo-(2H)-isoindol-2-yl)-alpha-ethylbenzeneacetic acid
- 4-(1,3-Dihydro-1-oxo-2H-isoindol-2-yl)-α-ethylbenzeneacetic acid
- Benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-α-ethyl-
- Ibustrin
- See more synonyms
- K 2930
- K 3920
Description:
Applications Indobufen is a platelet aggregation inhibitor. Indobufen is the anticoagulant drug and platelet aggregation inhibitor, which has anti-inflammatory analgesic effect. Indobufen is used as an antithrombotic.
References Diener, H., et al.: J. Neurol. Sci., 143, 1 (1996), Brainin, M., et al.: Eur. J. Neurol., 7, 5 (2005), Culebras, A., et al.: Neurology, 62, 1073 (2004), Lopez, A., et al.: Lancet, 367, 1747 (2006),
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
TRC
Long term storage:
Notes:
Chemical properties
Molecular weight:
295.33
Formula:
C18H17NO3
Color/Form:
Neat
InChI:
InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)
InChI key:
InChIKey=GEFDRROBUCULOD-UHFFFAOYSA-N
SMILES:
CC(=O)Nc1ccc(O)c(C(=O)O)c1
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TR-I576500 Indobufen
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
